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Genetics of serum urate 
concentrations and gout in a high-
risk population, patients with 
chronic kidney disease
Jiaojiao Jing1,2, Arif B. Ekici  3, Thomas Sitter4, Kai-Uwe Eckardt5, Elke Schaeffner6, Yong Li1, 
Florian Kronenberg  7, Anna Köttgen  1 & Ulla T. Schultheiss  1,8
We evaluated genetics of hyperuricemia and gout, their interaction with kidney function and 
medication intake in chronic kidney disease (CKD) patients. Genome-wide association studies (GWAS) 
of urate and gout were performed in 4941 CKD patients in the German Chronic Kidney Disease 
(GCKD) study. Effect estimates of 26 known urate-associated population-based single nucleotide 
polymorphisms (SNPs) were examined. Interactions of urate-associated variants with urate-altering 
medications and clinical characteristics of gout were evaluated. Genome-wide significant associations 
with serum urate and gout were identified for known loci at SLC2A9 and ABCG2, but not for novel loci. 
Effects of the 26 known SNPs were of similar magnitude in CKD patients compared to population-
based individuals, except for SNPs at ABCG2 that showed greater effects in CKD. Gene-medication 
interactions were not significant when accounting for multiple testing. Associations with gout in specific 
joints were significant for SLC2A9 rs12498742 in wrists and midfoot joints. Known genetic variants in 
SLC2A9 and ABCG2 were associated with urate and gout in a CKD cohort, with effect sizes for ABCG2 
significantly greater in CKD compared to the general population. CKD patients are at high risk of gout 
due to reduced kidney function, diuretics intake and genetic predisposition, making treatment to target 
challenging.
Gout is a progressive painful debilitating disease, and the most common inflammatory arthritis in many Western 
countries1. Population-based studies have identified genetic variants in multiple genes2 including SLC2A93–5 and 
ABCG25,6 associated with serum urate concentrations. Individuals with chronic kidney disease (CKD) represent 
a high-risk population for hyperuricemia and gout due to decreased renal clearance of urate and consecutive 
increase in serum urate concentrations. About ~25% of CKD patients from the prospective German Chronic 
Kidney Disease (GCKD) study reported a physician diagnosis of gout at study baseline and two thirds of patients 
were hyperuricemic7. This high prevalence of gout is most relevant given that CKD affects about 10% of the adult 
population in many countries8.
Despite the importance of CKD as a risk factor for gout, knowledge about genetic determinants of serum urate 
in the setting of CKD is limited. One candidate gene study that focused on 11 urate transporters reported that 
the strength of association - as quantified by the association p-value - between genetic variants in ABCG2 was 
stronger in patients with CKD compared to 481 population-based individuals, while the opposite was observed 
for variants in SLC2A99. While the authors hypothesized that this could be interpreted by a compensatory role 
of the ABCG2 transporter in the intestine in the setting of reduced kidney function, they did not formally 
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compare effect sizes or test for differences in effect. Additional aspects of urate genetics in CKD that have not 
been addressed are interactions between genetic risk variants for gout and medication intake as well as clinical 
characteristics of gout attacks.
We aimed to evaluate the genetic underpinnings of hyperuricemia and gout in a large cohort of CKD patients, 
by carrying out genome-wide association studies (GWAS) of serum urate concentrations and gout. Effect sizes of 
known urate-associated variants detected in the general population were formally compared to their counterparts 
among CKD patients. Interactions between medications influencing serum urate concentrations and commonly 
prescribed in CKD were evaluated, and associations between genetic risk variants and clinical characteristics of 
gout were examined.
Results
Study population. Baseline clinical characteristics of 4,941 GCKD study participants with complete clinical 
information required for the GWAS are summarized in Table 1. A quarter of the patients reported diagnosis of 
gout at study baseline. Participants with gout compared to those without gout were significantly (p-value < 0.05) 
more likely to be male, older, have a higher BMI, be hypertensive, diabetic, have higher triglyceride levels and 
have lower eGFR. There were no significant differences in serum urate concentrations between the two groups, 
but patients with gout were significantly more likely to be treated with allopurinol compared to those without 
gout7. The most pronounced significant differences were observed for eGFR, age, gender, BMI, and diuretic and 
gout medication intake.
Genome-wide association analyses. We conducted GWAS for serum urate concentrations and gout 
using 9,281,895 autosomal SNPs. A quantile-quantile plot comparing observed and expected p-values from the 
serum urate GWAS showed SNPs with very low observed p-values for serum urate and gout. There was no infla-
tion of median test statistics, consistent with the absence of systematic errors (Supplemental Fig. 1). In the serum 
urate GWAS, three loci showed genome-wide significant associations (p-value < 5.0E-08, Fig. 1). Variants with 
the lowest association p-values mapped into the previously reported genes SLC2A9 (rs13111638) and ABCG2 
(rs2231142). Per each minor allele copy, serum urate concentrations were 0.40 mg/dl (23.79 μmol/L) higher 
for ABCG2 rs2231142 and 0.31 mg/dl (18.44 μmol/L) lower for SLC2A9 rs13111638 (Table 2). A third locus, 
URI1, had not been detected in prior population-based studies. Because CKD cohorts with gout information 
were not available for replication, and because our findings supported the presence of similar associated loci in 
population-based and CKD patient studies, the index SNP at this locus was investigated in the well-powered 
summary results from GWAS meta-analysis of serum urate of >140,000 participants in the GUGC Consortium2. 
The association was not significant and therefore not followed up on. Odds Ratios (OR) for the associations with 
gout from the GWAS of gout were 1.54 (95% CI: 1.34; 1.78) for ABCG2 rs2231142 and 0.77 (95% CI: 0.68; 0.86) 
for SLC2A9 rs13111638 (Table 2). Leading SNPs with association p-values of p < 1.0E-06 (suggestive significance) 
are listed in Supplemental Tables 1 and 2.
Comparison of genetic effects to the general population. Next we compared the effect sizes of 26 
SNPs known to be associated with serum urate in the general population2 to the results from the GWAS in the 
GCKD study. Of the 26 SNPs discovered among approximately 140,000 individuals, seven SNPs were nominally 
associated (p-value < 0.05) with serum urate among CKD patients in the GCKD study (Supplemental Table 3) 
and two SNPs, at ABCG2 and at SLC2A9, were significant after adjusting for multiple testing (p-value < 1.9E-03, 
Characteristic Overall (n = 4941) No gout (n = 3724) Gout (n = 1217) P-value
eGFR, ml/min/1.73 m2 49.5 ± 18.1 51.0 ± 18.9 44.9 ± 14.8 <2.2e-16
Age 60.1 ± 12.0 59.1 ± 12.6 63.1 ± 9.1 <2.2e-16
Female, n (%) 39.8% 44.5% 25.4% <2.2e-16
BMI, kg/m2 29.8 ± 6.0 29.3 ± 5.8 31.6 ± 6.1 <2.2e-16
Hypertension, n (%) 96.2% 95.4% 98.6% 4.9E-07
Systolic BP, mmHg 139.4 ± 20.4 138.8 ± 20.1 141.2 ± 21.1 5.2E-04
Cholesterol, mg/dL 211.3 ± 53.0 213.0 ± 53.3 206.1 ± 51.8 6.0E-05
Triglycerides, mg/dL 168.1 (118.2, 239.0) 161.2 (113.8, 229.3) 193.6 (133.4, 270.4) 6.3E-15
CHD, n (%) 19.9% 17.5% 27.0% 6.4E-13
DM 2, n (%) 24.3% 21.8% 32.1% 4.3E-13
Serum urate, mg/dL 7.21 ± 1.92 7.20 ± 1.91 7.23 ± 1.96 7.3E-01
Hyperuricemia, n (%) 61.0% 57.2% 62.3% 1.8E-03
Alcohol intake, moderate to large amount 19.0% 17.3% 24.1% 9.4E-07
Diuretic intake, n (%) 61.0% 56.9% 73.7% <2.2e-16
Gout medication intake, n (%) 32.8% 20.8% 69.5% <2.2e-16
Table 1. Study sample characteristics of GCKD participants with complete urate, gout and genotype 
information. Continuous variables are mean (SD) unless otherwise noted. N = 4941, except for systolic blood 
pressure (n = 4913), cholesterol (n = 4935), triglycerides (n = 4933). Estimated glomerular filtration rate 
(eGFR), body mass index (BMI), systolic blood pressure (systolic BP), coronary heart disease (CHD), diabetes 
mellitus type 2 (DM 2); p-value for comparison of each characteristic in individuals with and without gout.
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0.05/26). Effect sizes of the genetic associations on serum urate were of similar magnitude in the GCKD study 
and the population-based meta-analysis for most SNPs, with high correlations across all risk variants observed 
for both urate (Pearson correlation coefficient 0.78 (Fig. 2, Panel A)) and gout (correlation 0.82 (Fig. 2, Panel B)). 
The two SNPs that were significantly associated in the GCKD study, at SLC2A9 and ABCG2, were tested for dif-
ferences in genetic effect sizes on serum urate. The association for rs2231142 in ABCG2 was significantly higher 
in CKD patients compared to the results from the general population (effect 0.4 mg/dl in CKD vs. 0.22 mg/dl in 
population-based studies, p-value for difference = 1.5E-03; Supplemental Table 4).
Figure 1. Manhattan plot for GWAS of serum urate (A) and gout (B) from the regression models. Y-axis: 
association p-values; x-axis: plotted SNPs by chromosomal position. Continuous line: genome-wide significance 
level (5E-8). Dashed line: suggestive significance level (1E-5). Data from 1000 Genomes imputation-based 
GWAS in CKD subjects of European-ancestry.
SNP Funct.
Closest 
Genes Chr Position A1 A2
Freq.
A1
Urate Gout
effect SE p-value OR 95% CI p-value
rs2231142 exonic ABCG2 4 89052323 T G 0.11 0.40 0.05 8.8E-14 1.54 1.34, 1.78 5.3E-09
rs13111638 intronic SLC2A9 4 9996890 T C 0.19 −0.31 0.04 2.0E-13 0.77 0.68, 0.86 2.9E-05
Table 2. Association estimates for index SNPs associated at genome-wide significance with serum urate, and 
their corresponding association with gout. SNP indicates the SNP with the lowest p-value for urate; the index 
SNP at SLC2A9 for gout was rs59834205 (p-value 1.36E-07, LD with rs13111638: r2 = 0.60, D′ = 0.79, using 
1000 G phase 3); the index SNP at ABCG2 for gout was rs4148155 (p-value 4.54E-09; LD with rs2231142: 
r2 = 0.99, D′ = 1, using 1000 G phase 3). Estimates for rs4148155 and rs59834205 are shown in Supplemental 
Table 2. Abbreviations: Funct., function; Chr, chromosome; A1, coded allele; A2, non-coded allele; Freq.A1, the 
frequency of the coded allele; effect, effect of A1; SE, standard error; OR, odds ratio; 95% CI, 95% confidence 
interval. Associations with urate were adjusted for age, sex, log(eGFR), BMI, significant principal components 
(p < 0.05), intake of diuretics and gout medication, while associations with gout were adjusted for age, sex, 
log(eGFR), BMI, and intake of diuretics. Associations were filtered for plausibility and quality.
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SNP-kidney-function interaction. Although genetic effects of most variants on serum urate discov-
ered in the general population were similar among CKD patients, the effect of individual variants on serum 
urate may change as eGFR declines. We therefore compared associations of the two genome-wide significant 
urate-associated SNPs across different categories of eGFR. When stratified by eGFR, the minor T allele of 
rs2231142 in ABCG2 was significantly associated with serum urate concentrations in each stratum and showed 
a trend for larger effects at eGFR values <30 ml/min/1.73 m2 (Supplemental Table 5). A statistical test for inter-
action across the entire eGFR range was not significant. The SNP in SLC2A9 did not show any clear effect size 
differences or interactions with categories of eGFR.
Gene-environment interaction of candidate variants and medications. Several medications 
commonly prescribed to CKD patients are known to affect serum urate concentrations. We therefore assessed 
potential effect modifications of these medications on the associations of urate-associated SNPs mapping into 
the interacting transport proteins with serum urate and gout. The intake of allopurinol, thiazide diuretics, loop 
diuretics, potassium sparing diuretics and losartan was evaluated for interaction with known urate-associated 
SNPs mapping into the loci for SLC2A9, ABCG2, SLC17A1, and SLC22A12 (p < 2.5E-03, 0.05/(4 * 5)). Table 3 
shows results for the interaction between all SNPs and medications that showed at least a nominally significant 
(p < 0.05) SNP* medication interaction, namely thiazides and loop diuretics. Two models were evaluated because 
of polypharmacy in patients of moderate and advanced CKD. One compared the effect between patients taking 
the respective medication to those not taking it, and one compared the effect between patients who were only 
taking this medication to patients not taking any of the evaluated medications. Three of the interactions achieved 
nominal significance in at least one comparison and had similar effect size differences in both types of compar-
isons, but none of these interactions were statistically significant after correcting for multiple testing. A detailed 
list of all tested gene-medication interactions can be found in Supplemental Table 6.
Association with clinical characteristics of gout. Hyperuricemia can lead to monosodium urate 
crystal formation, influenced by factors such as temperature, pH, salt concentration, and cartilage matrix com-
ponents. Processes of crystal formation and initiation of joint inflammation are incompletely understood and 
more underlying factors seem to be at play. We investigated whether genetic effects were more clearly discernible 
in joints across which temperature, weight pressure or usage strain may differ for the genome-wide significant 
urate-associated index SNPs at ABCG2 and SLC2A9. The SNP rs12498742 in SLC2A9 was significantly (p < 3.1E-
03, 0.05/(2 * 8)) associated with gout affection in wrist and midfoot joints (Table 4). The strongest effect was 
observed with gout affection of the wrists (OR 0.35, 95% CI 0.18–0.60, p = 4.7E-04), with each copy of the G 
allele associated with 65% lower odds of gout affection of the wrists. Because of the lower minor allele frequency, 
subgroups for rs2231142 in ABCG2 were small, and only one joint localization showed a nominally significant 
(p < 0.05) association (ankles, OR = 1.47, 95% CI 1.02–2.08, p = 3.2E-02). The possibility to study a clear pattern 
of joint affection in relation to genetic risk variants therefore requires study in even larger samples.
Discussion
In this study of serum urate and gout genetics in CKD, we found genome-wide significant associations with SNPs 
in two previously identified loci, ABCG2 and SLC2A9. The magnitude of genetic effects identified in previous 
population-based studies was generally similar except for ABCG2, where effects were larger in CKD patients. 
Effect modification of risk variants in ABCG2 and SLC2A9 by eGFR categories or intake of urate-altering med-
ications was not significant after accounting for multiple testing, but there were several nominally significant 
gene-by-medication interactions. Genetic associations with detailed information about the affected joint locali-
zation showed significant associations for the SLC2A9 risk allele with gout of the wrists and midfoot joints.
Figure 2. Scatter plot comparing effect sizes of 26 known urate-associated SNPs from a meta-analysis of 
population-based studies (X-axis) to those of CKD patients (Y-axis). Upper panel shows the association with urate 
(Panel A), lower panel shows the associations with gout (Panel B). Gout effects are presented on the log odds scale.
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SLC2A9 and ABCG2 are the two most prominent players in gout explaining ~5% of variance in serum urate 
levels10. GLUT9, affecting uric acid transport through urate reabsorption at the basolateral membrane11 of renal 
proximal tubules, is encoded by SLC2A9. The ABCG2 transporter, encoded by ABCG2 and localized to the 
brush border of renal proximal tubules and intestinal cells, functions to extrude urate in an ATP-dependent 
fashion2,5,12–18.
Similar effect sizes of the lead SNP in SLC2A9 were found when comparing our results to those from 
population-based studies2,4,5 and one previous study in individuals with CKD stage 3. The previous study of CKD 
patients by Bhatnagar and colleagues evaluated a bi-racial study population with fewer and younger patients over-
all and smaller patient numbers in the European ancestry subgroup9,19. Other differences include a genome-wide 
screen in our study, allowing for the comparison of effect sizes outside of the 11 transporter genes they studied, 
and the detailed clinical characterization of gout in our study. While Bhatnagar and colleagues9 reported that the 
index variant in ABCG2 in CKD patients was associated with serum urate with similar effect sizes but at lower 
p-values when compared to population-based studies2,4,5, we found that the effect sizes were almost twice as large 
in CKD patients compared to population-based samples. Differences between the studies, most importantly dif-
ferences in ethnic composition and the proportion of individuals with diabetes, but also in age may account for 
this difference, but random variation should also be taken into consideration.
Besides renal excretion, recent findings demonstrated physiological and pathophysiological roles of ABCG2 
on intestinal urate excretion in humans9,20, where the degree of intestinal ABCG2 dysfunction showed strong 
associations with the severity of hyperuricemia in the setting of end-stage renal disease20. We further tested 
whether the risk conferred by rs2231142 in ABCG2 was altered in the setting of reduced eGFR using stratified and 
interaction analyses. A trend for higher genetic effects on serum urate levels in individuals with eGFR <30 ml/
min/1.73 m2 lends some support to the importance of intestinal ABCG2 function, but results from our interaction 
analysis with eGFR did not support the hypothesis that genetic effects of ABCG2 on serum urate become larger 
i.e. more important in individuals with CKD compared to the general population in a linear fashion.
To our knowledge, this is the first study to quantify the interaction between gout risk genes and sub-classes 
of diuretics or allopurinol. Diuretics are widely used for CKD management, hypertension and heart failure21, the 
latter being frequent comorbidities in patients of the GCKD study. Allopurinol is the most frequently prescribed 
urate-lowering therapy in the GCKD study despite its side effects and a reduced dose recommendation in CKD. 
Our findings are suggestive of a greater impact of ABCG2 risk alleles among those using loop diuretics. The 
observation that adjustment for allopurinol intake was important in detecting genetic effects on gout in this study 
implies that allopurinol is a well working drug regardless of the observed SLC2A9 and ABCG2 genotype.
Gene-environment interaction-studies have shown conflicting results for the role of genetic risk factors in 
gout patients using diuretics22–24, likely related to polypharmacy in CKD and limited sample sizes. Such sample 
sizes have to be several times larger than the ones needed to detect main gene effects, highlighting the need 
for future, bigger cohort studies to explore gene-environment interactions. Worldwide rates of initiation and 
SNP Medication
With this medication Without this medication All (SNP × medication)
effect SE p-value n effect SE p-value n effect SE p-value n
SLC2A9  
rs12498742 (G)
thiazide −0.23 0.08 2.7E-03 1570 −0.33 0.05 7.2E-13 3371 0.11 0.08 2.0E-01 4941
loop diuretic −0.37 0.07 1.0E-07 1900 −0.25 0.05 1.5E-07 3041 −0.08 0.08 2.9E-01 4941
ABCG2  
rs2231142 (T)
thiazide 0.37 0.10 3.1E-04 1570 0.43 0.06 3.0E-12 3371 −0.06 0.11 6.0E-01 4941
loop diuretic 0.58 0.10 2.1E-09 1900 0.30 0.06 9.3E-07 3041 0.22 0.11 4.4E-02 4941
SLC17A1  
rs1165151 (G)
thiazide 0.14 0.06 2.5E-02 1570 0.03 0.04 4.4E-01 3371 0.10 0.07 1.5E-01 4941
loop diuretic −0.03 0.06 6.2E-01 1900 0.11 0.04 3.1E-03 3041 −0.16 0.07 2.0E-02 4941
NRXN2/ 
SLC22A12  
rs478607 (A)
thiazide −0.13 0.09 1.5E-01 1570 −0.12 0.05 2.1E-02 3371 −0.02 0.10 8.7E-01 4941
loop diuretic −0.29 0.08 4.5E-04 1900 −0.01 0.05 7.9E-01 3041 −0.27 0.09 3.6E-03 4941
SNP Medication
Only this medication No medication** All (SNP × medication)
effect SE p-value n effect SE p-value n effect SE p-value n
SLC2A9  
rs12498742 (G)
thiazide −0.06 0.12 5.9E-01 604 −0.29 0.06 3.9E-06 1503 0.23 0.12 6.3E-02 2107
loop diuretic −0.44 0.11 6.3E-05 589 −0.29 0.06 3.9E-06 1503 −0.17 0.12 1.6E-01 2092
ABCG2  
rs2231142 (T)
thiazide 0.35 0.16 3.3E-02 604 0.27 0.09 1.9E-03 1503 0.11 0.17 5.1E-01 2107
loop diuretic 0.66 0.17 1.6E-04 589 0.27 0.09 1.9E-03 1503 0.40 0.18 2.4E-02 2092
SLC17A1  
rs1165151 (G)
thiazide 0.24 0.10 2.1E-02 604 0.02 0.05 6.7E-01 1503 0.21 0.11 4.6E-02 2107
loop diuretic −0.02 0.10 8.8E-01 589 0.02 0.05 6.7E-01 1503 −0.06 0.10 5.9E-01 2092
NRXN2/ 
SLC22A12  
rs478607 (A)
thiazide 0.04 0.14 7.5E-01 604 −0.03 0.07 6.9E-01 1503 0.08 0.14 5.8E-01 2107
loop diuretic −0.23 0.13 9.0E-02 589 −0.03 0.07 6.9E-01 1503 −0.21 0.14 1.4E-01 2092
Table 3. Selected interactions between known urate-associated risk alleles in urate transporters and 
medications known to affect serum urate concentrations. **No medication refers to not taking gout 
medications, diuretics and losartan. Associations were adjusted for age, sex, log(eGFR), BMI, and medications 
(gout medication, diuretics, losartan) other than the category being evaluated. The p-value for interaction 
adjusted for multiple testing was p < 2.5E-03. Rs12498742 (SLC2A9) is the reported index SNP from the GUGC 
Consortium and is in LD with rs13111638 (r2 = 0.74, D′ = 0.98).
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continuation of urate-lowering therapy are low and achievement of serum urate targets therefore infrequent7, 
although gout in combination with CKD7 contributes to poor health-related quality of life in these patients25.
Our results on joint location of acute gout flares do not clearly answer the hypothesis that genetic effects are 
more important in joints with higher weight pressure and usage strain26. However, sample sizes of each subgroup 
were small, highlighting the need of large gout research cohorts.
Strengths of our study are being one of the largest CKD cohorts world-wide, a detailed data collection, includ-
ing medication intake data and information from a validated gout questionnaire27–29 based on ACR criteria to 
survey gout, the availability of genome-wide genetic data for all patients allowing for an unbiased search for gout 
risk loci in the setting of CKD and a comprehensive examination of known genetic risk loci. Knowledge generated 
from CKD cohorts such as the GCKD study may inform future interventional trials that focus on reducing the 
burden of hyperuricemia and its associated progression of CKD and CVD30–34.
The present study has some limitations. Gout status was based on self-reported physician diagnosis of gout, 
possibly introducing some misclassification, but good sensitivity and reliability on self-reported gout has been 
reported previously7,35. Our analyses were based on a Caucasian patient population of mostly CKD stage 3, poten-
tially compromising generalizability. Sample sizes were small for interaction analyses, although the GCKD study 
is one of the largest observational cohorts of CKD patients world-wide. Pooled samples from different CKD 
cohorts with available information on serum urate concentrations and gout under the framework of CKD con-
sortia around the world could address this limitation36.
In summary, the known genetic associations at ABCG2 and SLC2A9 with serum urate and gout were repli-
cated in CKD patients with higher effect sizes for ABCG2 in patients with CKD compared to individuals from the 
general population. Interactions with medications and effect modification by eGFR categories were not significant 
after correcting for multiple testing. Affected joint localizations showed significant associations for SLC2A9 with 
wrists and midfoot joints. Patients with CKD are at risk for gout due to reduced kidney function, diuretics intake 
and genetics7. This large and complex patient group will become even more relevant in ageing populations and 
with increasing polypharmacy, and yet is still understudied.
Methods
Study population. The GCKD study is a multi-centric, prospective observational study of 5,217 CKD 
patients of European ancestry. Patients undergo regular, standardized study visits including questionnaires, phys-
ical examinations and biosampling by trained personnel. The GCKD study has implemented a data protection 
concept according to the data protection recommendations of the platform for technology and methods for net-
worked medical research (TMF; www.tmf-ev.de), supported by the German Ministry of Education and Research 
(www.bmbf.de). The study protocol was approved by local institutional review boards (1 ethics committee of the 
RWTH Aachen University, Aachen, Germany; 2 ethics committee of the Charité – University-Medicine, Berlin, 
Germany; 3 ethics committee of the Friedrich-Alexander University, Erlangen, Germany; 4 ethics committee 
of the Albert-Ludwigs-University, Freiburg, Germany; 5 ethics committee of the Friedrich-Schiller University, 
Jena, Germany; 6 ethics committee of the Hannover Medical School, Hannover, Germany; 7 ethics committee of 
the medical faculty, Ruprecht-Karls University, Heidelberg, Germany; 8 ethics committee of the medical faculty, 
Ludwig-Maximilians-University, Munich, Germany; 9 ethics committee of the Julius-Maximilians-University, 
Würzburg, Germany) at each participating academic institution, the data protection concept was reviewed by 
the data protection officer of the State of Hessen37 and the study was registered in the national registry of clinical 
studies (DRKS 0003971). All methods were carried out in accordance with relevant guidelines and regulations. 
Written informed consent was obtained for all participants. Study procedures and main baseline findings have 
been reported19,37. Prevalence and correlates of gout at study baseline were published elsewhere7.
A comprehensive gout questionnaire, implemented due to the high prevalence of gout observed at study base-
line, designed to meet the American College of Rheumatology (ACR) criteria used to survey gout and validated 
in previous observational studies of gout27–29, was used to assess clinical characteristics of patients, reporting a 
physician diagnosis of gout. The questionnaire covered physician diagnosis of gout, age of onset, annual number 
of attacks, attack duration, appearance of the affected joints, affected joint number and localization, presence of 
tophi, presence of crystals from fine-needle aspiration, presence of hyperuricemia, and family history of gout.
Affected 
joints Controls Cases
% of 
female 
cases
SLC2A9 rs12498742 (G) ABCG2 rs2231142 (T)
OR (95%CI) p-value OR (95%CI) p-value
shoulder 2007 19 26.3% 0.67 (0.25–1.47) 3.6E-01 0.38 (0.06–1.27) 1.9E-01
elbow 1988 38 10.5% 0.36 (0.15–0.73) 9.7E-03 0.92 (0.42–1.77) 8.2E-01
wrist 1959 67 23.9% 0.35 (0.18–0.60) 4.7E-04 1.18 (0.70–1.89) 5.1E-01
finger 1929 97 35.1% 0.73 (0.49–1.04) 9.7E-02 0.64 (0.37–1.04) 9.3E-02
knee 1928 98 7.1% 0.59 (0.39–0.87) 1.0E-02 1.41 (0.94–2.07) 8.7E-02
ankle 1903 123 14.6% 0.67 (0.47–0.93) 2.3E-02 1.47 (1.02–2.08) 3.2E-02
toe 1504 522 20.5% 0.92 (0.77–1.09) 3.3E-01 1.15 (0.93–1.43) 1.9E-01
midfoot 1816 210 21.4% 0.61 (0.46–0.80) 4.2E-04 1.31 (0.97–1.73) 7.0E-02
Table 4. Association between genome-wide significant SNPs and clinical characteristics of gout. Covariates 
included age, sex and log (eGFR). OR: Odds Ratio, 95% CI: 95% Confidence interval. For SLC2A9, rs12498742 is 
the previously reported index SNP from the GUGC Consortium; it is in LD with rs13111638 (r2 = 0.74, D′ = 0.98), 
the index SNP for SLC2A9 in the GCKD study. The p-value adjusted for multiple testing was p < 3.1E-03 (in bold).
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Genotyping, quality control and imputation. DNA was isolated from peripheral blood leukocytes and 
genotyped for 5,123 patients using the Illumina HumanOmni2.5-8 v1.2 BeadChip (Illumina, GenomeStudio, 
Genotyping Module Version 1.9.4) at the Helmholtz Center Munich. Standardized protocols were used for data 
cleaning38. Custom written scripts (R, Perl) and plink1.939 software was used for quality control. Quality control 
steps included call rate, sex check, mean heterozygosity, genetic ancestry and cryptic relatedness, leading to the 
exclusion of 89 samples. Single nucleotide polymorphism (SNP) exclusion criteria prior to imputation were a call 
rate of <0.96, deviation from Hardy-Weinberg equilibrium (p < 1.0E-05), and duplicate positions, yielding clean 
genotype data for 2,337,794 autosomal SNPs of the Omni 2.5 component from 5,034 patients. Genotypes were 
then imputed by pre-phasing40 and imputation with Impute2 (v2.3.1)41 using the 1000 Genomes Phase 3 version 
5 ALL as reference panel. After genotype imputation, 9,281,895 SNPs of high imputation quality (info score > 0.8) 
and a minor allele frequency of >0.01 were kept for association analyses to generate robust association statistics.
Statistical analyses. Patient characteristics were compared using t-tests for continuous and Chi-square tests 
for categorical variables.
Genome-wide association analyses. Single variant genome-wide association analyses were conducted using lin-
ear regression (urate) and logistic regression (gout), assuming an additive genetic model using genotype dosages 
to account for imputation uncertainty. For urate as the outcome, the regression model was adjusted for age, sex, 
estimated glomerular filtration rate (log(eGFR)), body mass index (BMI), intake of diuretics, and intake of gout 
medication. For gout as the outcome, the models was adjusted for age, sex, log(eGFR), BMI, and intake of diuret-
ics. In addition, principal components (PCs) were included as covariates when significantly (p < 0.05) associated 
with evaluated outcomes of the respective models.
Association analyses were performed using SNPTEST v2.542. Functional annotation of variants was conducted 
using ANNOVAR43.
Comparison of genetic effects to the general population. Twenty-six SNPs previously reported as associated with 
serum urate and replicated in a meta-analysis of mostly population-based cohorts in the Global Urate Genetics 
Consortium (GUGC)2 were used as candidate variants comparing their effect estimates in general populations 
with CKD patients in the GCKD study. Differences in effect estimates were computed for significantly asso-
ciated SNPs (in the GCKD study) after adjusting for multiple testing (p-value < 1.9E-03, 0.05/26) between 
population-based results and CKD patients using a 2-sample t-test. SNP associations were compared for minor 
allele frequencies, direction and magnitude and evaluated visually.
SNP-kidney-function interaction. Interactions were evaluated for SNPs showing genome-wide significant associ-
ations with serum urate in the GCKD study. According to the Kidney Disease: Improving Global Outcomes CKD 
guidelines44, eGFR was categorized into stages G1/2 (≥60 ml/min/1.73 m2), G3a (45–59 ml/min/1.73 m2), G3b 
(30–44 ml/min/1.73 m2) and G4/5 (˂30 ml/min/1.73 m2). For each of the four eGFR categories, the multivariable 
adjusted odds ratios (OR) and 95% confidence intervals (95% CI; all covariates as above except for eGFR) were 
compared. Interactions between genotype and eGFR category were evaluated by adding a SNP*eGFR category 
term to the model and evaluating its statistical significance.
Gene-environment interaction of candidate variants and medications. Gene environment-interactions were 
assessed for known urate-associated variants2 mapping into or near transporter genes reported to interact with 
medications (SLC2A9, ABCG2, NRXN2/SLC22A12 and SLC17A1)11 and medications known to affect urate con-
centration and commonly prescribed in CKD patients: allopurinol, thiazide diuretics, loop diuretics, potassium 
sparing diuretics and losartan. Allele dosages of imputed candidate SNPs were converted to the most likely gen-
otypes. Current medication intake was assessed for all GCKD patients and coded using Anatomical Therapeutic 
Chemical (ATC) codes. Allopurinol, thiazide diuretics, loop diuretics, potassium sparing diuretics and losartan 
intake were represented by codes M04AA01/M04AA51, C03A/C03B C03C, C03D and C09CA01.
For each SNP and medication combination, two types of stratified and interaction analyses were performed 
adjusted for age, sex, log(eGFR), BMI, intake of medications other than the evaluated class and PCs significantly 
associated with serum urate. Firstly, the stratified analyses by intake of the specific medication under evaluation 
and the analysis including an interaction term (SNP × specific medication) were assessed among all individuals. 
Secondly, the stratified analyses by intake of the specific medication under evaluation and the analysis includ-
ing an interaction term (SNP × specific medication) were assessed excluding individuals taking any of the other 
classes of medication under evaluation. Statistical significance for multiple testing (p < 2.5E-03) was obtained by 
dividing the significance threshold of 0.05 by the four tested SNPs multiplied with the five evaluated medications.
Association with clinical characteristics of gout. SNPs associated with serum urate at genome-wide significance 
were characterized for their associations with clinical characteristics of gout. Case numbers were only sufficient 
for a comparison of affected joint localizations across genotypes. Because of the limited sample size, only the 
most important covariates, age, sex and log(eGFR), were included. Statistical significance for multiple testing 
(p < 3.1E-03) was obtained by dividing the significance threshold of 0.05 by the two tested SNPs multiplied with 
the eight evaluated locations of gout attacks. All candidate variant analyses were conducted using R version 3.3.0.
Data availability. The data that supports the findings of this study is available for authors upon reasonable 
request and with permission of the Steering Committee of the GCKD study http://www.gckd.org.
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